Published in J Biol Chem on December 12, 1997
Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications. Blood (2007) 1.34
Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin. J Biol Chem (2010) 0.89
A surface plasmon resonance-based solution affinity assay for heparan sulfate-binding proteins. Glycoconj J (2008) 0.84
Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT. Blood (2011) 0.76
Involvement of human natural killer-1 (HNK-1) sulfotransferase in the biosynthesis of the GlcUA(3-O-sulfate)-Gal-Gal-Xyl tetrasaccharide found in α-thrombomodulin from human urine. J Biol Chem (2011) 0.76
Platelet factor 4 binds to vascular proteoglycans and controls both growth factor activities and platelet activation. J Biol Chem (2017) 0.75
Guidelines for the management of hemophilia. Haemophilia (2012) 5.16
Measuring circulating cell-derived microparticles. J Thromb Haemost (2004) 2.61
C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood (1993) 2.48
Hypotensive reactions to white cell-reduced plasma in a patient undergoing angiotensin-converting enzyme inhibitor therapy. Transfusion (1996) 2.22
Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost (2010) 2.12
Trends in healthcare incident reporting and relationship to safety and quality data in acute hospitals: results from the National Reporting and Learning System. Qual Saf Health Care (2009) 2.05
Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line. Mol Endocrinol (1994) 1.83
Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood (1998) 1.79
Crystal structures of zinc-free and -bound heme domain of human inducible nitric-oxide synthase. Implications for dimer stability and comparison with endothelial nitric-oxide synthase. J Biol Chem (1999) 1.65
Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest (1998) 1.58
Frequent aberrant immunoglobulin gene rearrangements in pro-B cells revealed by a bcl-xL transgene. Immunity (1996) 1.54
Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost (2013) 1.53
Antigen-induced lymphomagenesis: identification of a murine B cell lymphoma with known antigen specificity. J Immunol (1983) 1.49
Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. J Clin Invest (1993) 1.45
Polymorphism in the tissue factor region is associated with basal but not endotoxin-induced tissue factor-mRNA levels in leukocytes. J Thromb Haemost (2006) 1.43
Costs of NHS maternity care for women with multiple pregnancy compared with high-risk and low-risk singleton pregnancy. BJOG (2007) 1.43
Development of B-1 cells: segregation of phosphatidyl choline-specific B cells to the B-1 population occurs after immunoglobulin gene expression. J Exp Med (1994) 1.40
Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism. J Thromb Haemost (2006) 1.33
Lymphoma models for B cell activation and tolerance. III. Cell cycle dependence for negative signalling of WEHI-231 B lymphoma cells by anti-mu. J Exp Med (1986) 1.33
Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost (2012) 1.29
Iliofemoral deep venous thrombosis: safety and efficacy outcome during 5 years of catheter-directed thrombolytic therapy. J Vasc Interv Radiol (1997) 1.29
Chronic ethanol consumption alters the glutathione/glutathione peroxidase-1 system and protein oxidation status in rat liver. Alcohol Clin Exp Res (2001) 1.27
Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity. Thromb Res (2011) 1.25
The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking. J Thromb Haemost (2007) 1.16
Structurally specific heparan sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche. Blood (1998) 1.15
Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost (2014) 1.09
Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia (1999) 1.08
Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc Natl Acad Sci U S A (2000) 1.08
Eosinophil peroxidase oxidation of thiocyanate. Characterization of major reaction products and a potential sulfhydryl-targeted cytotoxicity system. J Biol Chem (2001) 1.08
Prospective study of sickle cell trait and venous thromboembolism incidence. J Thromb Haemost (2014) 1.08
Cross-reactive idiotypes and common antigen binding specificities expressed by a series of murine B-cell lymphomas: etiological implications. Proc Natl Acad Sci U S A (1985) 1.01
Lymphoma models for B cell activation and tolerance. IV. Growth inhibition by anti-Ig of CH31 and CH33 B lymphoma cells. Eur J Immunol (1986) 1.00
Pulmonary carcinoma with eosinophilia. Demonstration of a tumor-derived eosinophilopoietic factor. N Engl J Med (1983) 1.00
Superoxide-dependent cerebrovascular effects of homocysteine. Am J Physiol (1998) 0.99
Modulation of glycosaminoglycan addition in naturally expressed and recombinant human thrombomodulin. J Biol Chem (1994) 0.96
Challenges of rare disease research: limited patients and competing priorities. Haemophilia (2011) 0.94
Racial differences in endotoxin-induced tissue factor-triggered coagulation. J Thromb Haemost (2009) 0.93
Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost (2000) 0.92
Venous thromboembolism in malignant gliomas. J Thromb Haemost (2009) 0.92
The shape of thrombomodulin and interactions with thrombin as determined by electron microscopy. J Biol Chem (1996) 0.91
In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. J Thromb Haemost (2010) 0.91
Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. Haemophilia (2012) 0.91
Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia (2012) 0.91
High-level secretion of two antibody single chain Fv fragments by Pichia pastoris. J Immunol Methods (1997) 0.90
The contribution of red blood cells to thrombin generation in sickle cell disease: meizothrombin generation on sickled red blood cells. J Thromb Haemost (2013) 0.88
Comparison of case note review methods for evaluating quality and safety in health care. Health Technol Assess (2010) 0.88
Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington's disease patients and transgenic mouse models. Neurosci Lett (2000) 0.87
Lymphoma models for B cell activation and tolerance. V. Anti-Ig mediated growth inhibition is reversed by phorbol myristate acetate but does not involve changes in cytosolic free calcium. J Mol Cell Immunol (1987) 0.87
CD4+ T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects. Thromb Haemost (1999) 0.87
An in vitro model for toxin-mediated vascular leak syndrome: ricin toxin A chain increases the permeability of human endothelial cell monolayers. Blood (1997) 0.86
Iliopsoas haemorrhage in patients with bleeding disorders--experience from one centre. Haemophilia (2003) 0.86
The impaired responsiveness of chronic lymphatic leukemia lymphocytes to allogeneic lymphocytes. Blood (1973) 0.86
Role of eosinophil peroxidase in the origins of protein oxidation in asthma. Redox Rep (2000) 0.86
Tumor-induced eosinophilia and endocardial fibrosis: evidence for ectopic eosinophilopoietin production and toxic O2 metabolite-mediated endothelial damage. Trans Assoc Am Physicians (1982) 0.85
Single-center experience with rituximab as first-line immunosuppression for acquired hemophilia. J Thromb Haemost (2011) 0.85
Rapid transcriptional down-regulation of c-myc expression during cyclic adenosine monophosphate-promoted differentiation of leukemic cells. J Clin Invest (1987) 0.84
A paediatric telecardiology service for district hospitals in south-east England: an observational study. Arch Dis Child (2008) 0.83
Platelet factor 4 stimulates thrombomodulin protein C-activating cofactor activity. A structure-function analysis. J Biol Chem (1994) 0.83
Pilot study to test the efficacy and safety of activated recombinant factor VII (NovoSeven) in the treatment of refractory hemorrhagic cystitis following high-dose chemotherapy. Bone Marrow Transplant (2006) 0.83
Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria. Atherosclerosis (1996) 0.83
Acquired factor VII deficiency in hematopoietic stem cell transplant recipients. Bone Marrow Transplant (2002) 0.82
Identification of a highly conserved module in E proteins required for in vivo helix-loop-helix dimerization. J Biol Chem (1998) 0.82
Factor VIII inhibitory antibody in a patient with combined factor V/factor VIII deficiency. Haemophilia (2014) 0.82
CD4+ T cells specific for factor VIII as a target for specific suppression of inhibitor production. Adv Exp Med Biol (2001) 0.80
Prothrombotic phenotype diversity of human aortic endothelial cells in culture. Thromb Res (1992) 0.79
Clinical features and management of haemophilic pseudotumours: a single US centre experience over a 30-year period. Haemophilia (2013) 0.79
Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen. Cancer Res (1995) 0.79
Herpes virus infection of endothelium: new insights into atherosclerosis. Trans Am Clin Climatol Assoc (1992) 0.79
Whole blood tissue factor procoagulant activity remains detectable during severe aplasia following bone marrow and peripheral blood stem cell transplantation. Thromb Haemost (2001) 0.79
Effect of eosinophil peroxidase on airway epithelial permeability in the guinea pig. Pediatr Pulmonol (1996) 0.78
Construction and characterization of human CD7-specific single-chain Fv immunotoxins. J Immunol (1997) 0.78
Healthcare provided by a homeopath as an adjunct to usual care for Fibromyalgia (FMS): results of a pilot Randomised Controlled Trial. Homeopathy (2009) 0.78
Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies. J Immunol Methods (1996) 0.78
Antibodies specific for Ig idiotype, but not isotype, can substitute for antigen to induce IgM secretion by a B cell clone. Int Immunol (1990) 0.78
Successful liver transplantation in a patient with severe haemophilia A and a high-titre factor VIII inhibitor. Haemophilia (2004) 0.77
Serum immunoglobulin levels in chronic lymphatic leukaemia. Scand J Haematol (1974) 0.77
Quantitative measurement for endothelial constitutive nitric oxide synthase in cultured human endothelial cells. Nitric Oxide (1997) 0.77
Scratching the surface: endothelium as a regulator of thrombosis, fibrinolysis, and inflammation. J Lab Clin Med (1992) 0.77
Induction of tissue factor procoagulant activity in myelomonocytic cells inoculated by the agent of human granulocytic ehrlichiosis. Thromb Haemost (2000) 0.77
In vitro studies of ricin A-chain-induced vascular leak syndrome. Methods Mol Biol (2001) 0.77
Bacterial expression and characterization of an anti-desipramine single-chain antibody fragment. Int J Immunopharmacol (1996) 0.76
Identification of genes whose expression is altered during mitosuppression in livers of ethinyl estradiol-treated female rats. Carcinogenesis (1996) 0.76
Quinidine-induced neutropenia: report of a case with drug-dependent inhibition of granulocyte colony generation. Acta Haematol (1984) 0.76
Septic arthritis in males with haemophilia. Haemophilia (2008) 0.76
Characterization of an apparently synonymous F5 mutation causing aberrant splicing and factor V deficiency. Haemophilia (2014) 0.76
Rituximab for treatment of inhibitors in haemophilia A. A Phase II study. Thromb Haemost (2014) 0.76
Antineoplastic effects of Bordetella pertussis adenylate cyclase. Trans Assoc Am Physicians (1983) 0.76
Potential biomarkers of an exaggerated response to endotoxemia. Biomarkers (2007) 0.76
Circulating anticoagulant glycosaminoglycans in mucopolysaccharidosis type I. J Thromb Haemost (2008) 0.76
Novel inherited risk factors for venous thrombosis. J Lab Clin Med (1998) 0.75
Toward an understanding of the pathophysiologic mechanism of thrombosis in the antiphospholipid antibody syndrome. J Lab Clin Med (1995) 0.75
Molecular unraveling of von Willebrand's disease: still some way to go. J Lab Clin Med (1997) 0.75
More on: intensity of warfarin anticoagulation in APS. J Thromb Haemost (2005) 0.75
Interferon-alpha restores beta1-integrin-dependent, collagen-mediated platelet aggregation in a patient with chronic myelogenous leukemia. J Lab Clin Med (1998) 0.75
Serologic evidence that factor IX inhibitor in the plasma of hemophilia B patients detects factor IX on normal red cells. Transfusion (1996) 0.75
Visualization of immunotoxin-mediated tumor cell death in vivo. Clin Cancer Res (2001) 0.75
Simultaneous occurrence of posttransfusion purpura due to anti-HPA-1a and a delayed transfusion reaction due to anti-Jk(b) Transfusion (1997) 0.75